张宇超,吴铮,王韶屏,柳景华

• 1:首都医科大学附属北京安贞医院冠心病中心北京市心肺血管疾病研究所

摘要(Abstract)：

冠状动脉慢性完全闭塞（CTO）病变是经皮冠状动脉介入治疗（PCI）领域极具挑战的病变之一。在接受CTO-PCI的患者中，左心室收缩功能不全（LVSD）较为常见，这类患者通常表现出更为复杂的冠状动脉病变以及较多合并症，面临更高的PCI相关并发症发生风险，其血运重建临床获益亦存在争议。如何优化CTO-PCI策略及术后管理并改善患者结局，是当前亟待解决的问题。本文就LVSD合并CTO病变患者的临床特征、介入治疗获益、介入治疗策略、术后管理和近远期预后等方面进行综述，以期为优化LVSD合并CTO病变患者介入治疗的结局提供参考。

关键词(KeyWords)： 慢性完全闭塞;左心室收缩功能不全;经皮冠状动脉介入治疗

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金项目（81970291、82170344）

作者(Author): 张宇超,吴铮,王韶屏,柳景华

参考文献(References)：

• [1] Ybarra LF,Rinfret S,Brilakis ES,et al.Definitions and clinical trial design principles for coronary artery chronic total occlusion therapies:cto-arc consensus recommendations[J],Circulation,2021,143(5):479-500.DOI:10.1161/CIRCULATIONAHA.120.046754.
• [2]Toma A,Stahli BE,Gick M,et al.Comparison of benefit of successful percutaneous coronary intervention for chronic total occlusion in patients with versus without reduced(≤40%)left ventricular ejection fraction[J].Am J Cardiol,2017,120(10):1780-1786.DOI:10.1016/j.amjcard.2017.07.088.
• [3]Ishida K,Martin-Yuste V,Prat S,et al.Prognosis of patients with reduced left ventricular ejection fraction and chronic total occlusion according to treatment applied[J].Cardiovasc Revasc Med,2021,27:22-27.DOI:10.1016/j.carrey.2020.06.006.
• [4]Yamamoto K,Matsumura-Nakano Y,Shiomi H,et al.Effect of heart failure on long-term clinical outcomes after percutaneous coronary intervention versus coronary artery bypass grafting in patients with severe coronary artery disease[J].J Am Heart Assoc,2021,10(15):e021257.DOI:10.1161/JAHA.121.021257.
• [5]Kirtane AJ,Doshi D,Leon MB,et al.Treatment of higher-risk patients with an indication for revascularization:evolution within the field of contemporary percutaneous coronary intervention[J].Circulation,2016,134(5):422-431.DOI:10.1161/CIRCULATIONAHA,116.022061.
• [6]Tajstra M,Pyka L,Gorol J,et al.Impact of chronic total occlusion of the coronary artery on long-term progno sis in patients with ischemic systolic heart failure:insights from the COMMITHF registry[J].JACC Cardiovasc Interv,2016,9(17):1790-1797.DOI:10.1016/j.jcin.2016.06.007.
• [7]Albaeni A,Chatila KF,Thakker RA,et al.In-hospital outcomes of chronic total occlusion percutaneous coronary interventions in heart failure patients[J].Curr Prob1Cardiol,2023,48(2):101458.DOI:10.1016/j.cpcardiol.2022.101458.
• [8]Simsek B,Kostantinis S,Karacsonyi J,et al.Outcomes of chronic total occlusion percutaneous coronary intervention in patients with reduced left ventricular ejection fraction[J].Catheter Cardiovasc Interv,2022,99(4):1059-1064.DOI:10.1002/ccd.30097.
• [9]Kobayashi N,Ito Y,Kishi K,et al.Procedural results and in-hospital outcomes of percutaneous coronary intervention for chronic total occlusion in patients with reduced left ventricular ej ection fraction:sub-analysis of the Japanese CTO-PCI expert registry[J].Catheter Cardiovasc Interv,2022,100(1):30-39.DOI:10.1002/ccd.30231.
• [10]Galas si AR,Boukhris M,Toma A,et al.Percutaneous coronary intervention of chronic total occlusions in patients with low left ventricular ejection fraction[J].JACC Cardiovasc Interv,2017,10(21):2158-2170.DOI:10.1016/j.jcin.2017.06.058.
• [11]Guo L,Meng S,Lv H,et al.Long-term outcomes of successful recanalization compared with optimal medical therapy for coronary chronic total occlusions in patients with and without left ventricular systolic dysfunction[J].Front Cardiovasc Med,2021,8:654730.DOI:10.3389/fcvm.2021.654730.
• [12]Khariton Y,Airhart S,Salisbury AC,et al.Health status benefits of successful chronic total occlusion revascularization across the spectrum of left ventricular function:insights from the OPEN-CTO registry[J].JACC Cardiovasc Intern,2018,11(22):2276-2283.DOI:10.1016/j.jcin.2018.07.058.
• [13]Kook H,Yang JH,Cho JY,et al.Differential clinical impact of chronic total occlusion revascularization based on left ventricular systolic function[J].Clin Res Cardiol,2021,110(2):237-248.DOI:10.1007/s00392-020-01738-2.
• [14] Nombela-Franco L,Mitroi CD,Fernandez-Lozano I,et al.Ventricular arrhythmias among implantable cardioverterdefibrillator recipients for primary prevention:impact of chronic total coronary occlusion(VACTO Primary Study)[J].Circ Arrhythm Electrophysiol,2012,5(1):147-154.DOI:10.1161/CIRCEP.111.968008.
• [15]Nombela-Franco L,Iannaccone M,Anguera I,et al.Impact of chronic total coronary occlusion on recurrence of ventricular arrhythmias in ischemic secondary prevention implantable cardioverter-defibrillator recipients(VACTO Secondary Study):insights from coronary angiogram and electrogram analysis[J].JACC Cardiovasc Interv,2017,10(9):879-888.DOI:10.1016/j.jcin.2017.02.008.
• [16]Iannaccone M,Nombela-Franco L,Gallone G,et al.Impact of successful chronic coronary total occlusion recanalization on recurrence of ventricular arrhythmias in implantable cardioverterdefibrillator recipients for ischemic cardiomyopathy(VACTO PCI Study)[J].Cardiovasc Revasc Med,2022,43:104-111.DOI:10.1016/j.carrev.2022.03.029.
• [17]Liao R,Li Z,Wang Q,et al.Revascularization of chronic total occlusion coronary artery and cardiac regeneration[J].Front Cardiovasc Med,2022,9:940808.DOI:10.3389/fcvm.2022.940808.
• [18]Behnes M,Mashayekhi K,Kuche P,et al.Prognostic impact of coronary chronic total occlusion on recurrences of ventricular tachyarrhythmias and ICD therapies[J].Clin Res Cardiol,2021,110(2):281-291.DOI:10.1007/s00392-020-01758-y.
• [19]Sachdeva R,Agrawal M,Flynn SE,et al.The myocardium supplied by a chronic total occlusion is a persistently ischemic zone[J].Catheter Cardiovasc Interv,2014,83(1):9-16.DOI:10.1002/ccd.25001.
• [20]Ramunddal T,Hoebers LP,Henriques JP,et al.Prognostic impact of chronic total occlusions:a report from SC AAR(Swedish Coronary Angiography and Angioplasty Registry)[J].JACC Cardiovasc Interv,2016,9(15):1535-1544.DOI:10.1016/j.jcin.2016.04.031.
• [21]Brilakis ES,Mashayekhi K,Tsuchikane E,et al.Guiding principles for chronic total occlusion percutaneous coronary intervention[J].Circulation,2019,140(5):420-433.DOI:10.1161/CIRCULATIONAHA.119.03 9797.
• [22]Azzalini L,Karmpaliotis D,Santiago R,et al.Contemporaryissues in chronic total occlusion percutaneous coronary intervention[J].JACC Cardiovasc Interv,2022,15(1):1-21.DOI:10.1016/j.jcin.2021.09.027.
• [23]Ybarra LF,Rinfret S.Why and how should we treat chronic total occlusion? Evolution of state-of-the-art methods and future directions[J].Can J Cardiol,2022,38(10 Suppl 1):S42-S53.DOI:10.1016/j.cjca.2020.10.005.
• [24] Yeh RW,Tamez H,Secemsky EA,et al.Depression and angina among patients undergoing chronic total occlusion percutaneous coronary intervention[J].JACC Cardiovasc Interv,2019,12(7):651-658.DOI:10.1016/j.jcin.2018.12.029.
• [25]Megaly M,Saad M,Tajti P,et al.Meta-analysis of the impact of successful chronic total occlusion percutaneous coronary intervention on left ventricular systolic function and reverse remodeling[J].J Interv Cardiol,2018,31(5):562-571.DOI:10.1111/joic.12538.
• [26]赵帅,陈蓉,曹家豪,等.成功经皮冠状动脉介入治疗对冠状动脉慢性完全闭塞病变合并左心室射血分数降低患者生活质量的影响[J].中国介入心脏病学杂志,2022,30(4):259-264.DOI:10.3969/j.issn.1004-8812.2022.04.003.
• [27]Wu X,Cai J,Zhang Q,et al.Assessing the clinical influence of chronic total occlusions(CTOs)revascularization and the impact of vascularization completeness on patients with left ventricular(LV)systolic dysfunction[J].Comput Intell Neurosci,2022,2022:9128206.DOI:10.1155/2022/9128206.
• [28]Pinto G,Fragasso G,Gemma M,et al.Long-term clinical effects of recanafization of chronic coronary total occlusions in patients with left ventricular systolic dysfunction[J].Catheter Cardiovasc Interv,2020,96(4):831-838.DOI:10.1002/ccd.28850.
• [29] Velazquez E J,Lee KL,Deja MA,et al.Coro nary-artery bypass surgery in patients with left ventricular dysfunction[J].N EngL J Med,2011,364(17):1607-1616.DOI:10.1056/NEJMoa1100356.
• [30]Velazquez EJ,Lee KL,Jones RH,et al.Coronary-artery bypass surgery in patients with ischemic cardiomyopathy[J].N Engl J Med,2016,374(16):1511-1520.DOI:10.1056/NEJMoa1602001.
• [31]Perera D,Clayton T.O'Kane PD,et al.Percutaneous revascularization for ischemic left ventricular dysfunction[J].N Engl J Med,2022,387(15):1351-1360.DOI:10.1056/NEJMoa2206606.
• [32] Lee SW,Lee PH,Ahn JM,et al.Randomized trial evaluating percutaneous coronary intervention for the treatment of chronic total occlusion[J].Circulation,2019,139(14):1674-1683.DOI:10.1161/CIRCULATIONAHA.118.031313.
• [33] Werner GS,Martin-Yuste V,Hildick-Smith D,et al.A randomized multicentre trial to compare revascularization with optimal medical therapy for the treatment of chronic total coronary occlusions[J].Eur Heart J,2018,39(26):2484-2493.DOI:10.1093/eurheartj/ehy220.
• [34]Werner GS,Hildick-Smith D,Martin Yuste V,et al.Threeyear outcomes of a randomized multicentre trial comparing revascularization and optimal medical therapy for chronic total coronary occlusions(EuroCTO)[J].Euro Intervention,2023,19(7):571-579.DOI:10.4244/EIJ-D-23-00312.
• [35]Henriques JP,Hoebers LP,Ramunddal T,et al.Percutaneous intervention for concurrent chronic total occlusions in patients with STEMI:the EXPLORE trial[J].J Am Coll Cardiol,2016,68(15):1622-1632.DOI:10.1016/j.jacc.2016.07.744.
• [36]Mashayekhi K,Nührenberg TG,Toma A,et al.A randomized trial to assess regional left ventricular function after stent implantation in chronic total occlusion:the REVASC trial[J].JACC Cardiovasc Interv,2018,11(19):1982-1991.DOI:10.1016/j.j cin.2018.05.041.
• [37]Obedinskiy AA,Kretov El,Boukhris M,et al.The IMPACTOR-CTO trial[J].JACC Cardiovasc Interv,2018,11(13):1309-1311.DOI:10.1016/j.jcin.2018.04.017.
• [38]Ramunddal T,Holck EN,Karim S,et al.International randomized trial on the effect of revascularization or optimal medical therapy of chronic total coronary occlusions with myocardial ischemia-ISCHEMIA-CTO trial-rationale and design[J].Am Heart J,2023,257:41-50.DOI:10.1016/j.ahj.2022.11.016.
• [39]Tajti P,Karmpaliotis D,Alaswad K,et al.The hybrid approach to chronic total occlusion percutaneous coronary intervention:update from the PROGRESS CTO registry[J].JACC Cardiovasc Interv,2018,11(14):1325-1335.DOI:10.1016/j.jcin.2018.02.036.
• [40] Sengodan P,Davies RE,Matsuno S,et al.Chronic total occlusion interventions in patients with reduced ejection fraction[J].Curr Cardiol Rep,2023,25(2):43-50.DOI:10.1007/s11886-022-01832-Z.
• [41]Brennan JM,Curtis JP,Dai D,et al.Enhanced mortality risk prediction with a focus on high-risk percutaneous coronary intervention:results from 1,208,137 procedures in the NCDR(National Cardiovascular Data Registry)[J].JACC Cardiovasc Interv,2013,6(8):790-799.DOI:10.1016/j.jcin.2013.03.020.
• [42]Simsek B,Kostantinis S,Karacsonyi J,et al.Predicting periprocedural complications in chronic total occlusion percutaneous coronary intervention[J].JACC Cardiovasc Interv,2022,15(14):1413-1422.DOI:10.1016/j.jcin.2022.06.007.
• [43]Danek BA,Basir MB.O'Neill WW,et al.Mechanical circulatory support in chronic total occlusion percutaneous coronary intervention:insights from a multicenter U.S.registry[J].J Invasive Cardiol,2018,30(3):81-87.
• [44]Ly HQ,Noly PE,Nosair M,et al.When the complex meets the high-risk:mechanical cardiac support devices and percutaneous coronary interventions in severe coronary artery disease[J].Can J Cardiol,2020,36(2):270-279.DOI:10.1016/j.cjca.2019.12.001.
• [45] Tajti P,Alaswad K,Karmpaliotis D,et al.In-hospital outcomes of attempting more than one chronic total coronary occlusion through percutaneous intervention during the same procedure[J].Am J Cardiol,2018,122(3):381-387.DOI:10.1016/j.amicard.2018.04.021.
• [46]Kalra S,Doshi D,Sapontis J,et al.Outcomes of retrograde chronic total occlusion percutaneous coronary intervention:a report from the OPEN-CTO registry[J].Catheter Cardiovasc Interv,2021,97(6):1162-1173.DOI:10.1002/ccd.29230.
• [47]葛均波,葛雷,霍勇,等.中国冠状动脉慢性完全闭寒病变介入治疗推荐路径更新[J].中国介入心脏病学杂志,2021,29(6):302-305.DOI:10.3969/j.issn.1004-8812.2021.06.002.
• [48]张涛,张宇晨,冯婷婷,等.自制圈套器在冠状动脉慢性完全闭塞病变逆向介入治疗中的应用[J].中国介入心脏病学杂志,2023,31(2):89-94.DOI:10.3969/j.issn.1004-8812.2023.02.002.
• [49]Zein R,Seth M,Othman H,et al.Association of operatorand hospital experience with procedural success rates and outcomes in patients undergoing percutaneous coronary interventions for chronic total occlusions[J].Circ Cardiovasc Interv,2020,13(8):e008863.DOI:10.1161/CIRCINTERVENTIONS.119.008863.
• [50]McDonagh TA,Metra M,Adamo M,et al.2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure[J].Eur Heart J,2023,44(37):3627-3639.DOI:10.1093/eurheartj/ehad195.
• [51]Heidenreich PA,Bozkurt B,Aguilar D,et al.2022 AHA/ACC/HFSA guideline for the management of heart failure:a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines[J].Circulation,2022,145(18):e895-e1032.DOI:10.1161/CIR.0000000000.001063
• [52]McDonagh TA,Metra M,Adamo M,et al.2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure[J],Eur Heart J,2021,42(36):3599-3726.DOI:10.109 3/eurheartj/ehab 368.
• [53]Furtado RHM,Fagundes AA Jr,Oyama K,et al.Effect of evolocumab in patients with prior percutaneous coronary intervention[J].Circ Cardiovasc Interv,2022,15(3):e0113 82.DOI:10.1161/CIRCINTERVENTIONS.121.011382.
• [54]Schwartz GG,Steg PG,Szarek M,et al.Alirocumab and cardiovascular outcomes after acute coronary syndrome[J].N Engl J Med,2018,379(22):2097-2107.DOI:10.1056/NEJMoa1801174.
• [55]Raber L,Ueki Y,Otsuka T,et al.Effect of alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction:the PACMAN-AMI randomized clinical trial[J 1.JAMA,2022,327(18):1771-1781.DOI:10.1001/j ama.2022.5218.
• [56]Packer M,Metra M.Guideline-directed medical therapy for heart failure does not exist:a non-judgmental framework for describing the level of adherence to evidence-based drug treatments for patients with a reduced ejection fraction[J].Eur J Heart Fail,2020,22(10):1759-1767.DOI:10.1002/ejhf.1857.
• [57]Greene SJ,Butler J,Albert NM,et al.Medical therapy for heart failure with reduced ejection fraction:the CHAMP-HF registry[J].J Am Coll Cardiol,2018,72(4):351-366.DOI:10.1016/j.jacc.2018.04.070.
• [58]Hübinette C,Lund LH,Gadler F,et al.Awareness of indications for device therapy among a broad range of physicians:a survey study[J].Europace,2014,16(11):1580-1586.DOI:10.1093/europace/eut416.
• [59]Li Z,Liu Q,Zhou S,et al.Enhancing myocardial function with cardiac contractility modulation:potential and challenges[J].ESC Heart Fail,2024,11(1):1-12.DOI:10.1002/ehf2.14575.
• [60]Giallauria F,Cuomo G,Parlato A,et al.A comprehensive individual patient data meta-analysis of the effects of cardiac contractility modulation on functional capacity and heart failurerelated quality of life[J].ESC Heart Fail,2020,7(5):2922-2932.DOI:10.1002/ehf2.12902.
• [61]Razeghian-Jahromi I,Matta AG,Canitrot R,et al.Surfing the clinical trials of mesenchymal stem cell therapy in ischemic cardiomyopathy[J].Stem Cell Res Ther,2021,12(1):361.DOI:10.1186/s 13287-021-02443-1.
• [62]Shen T,Xia L,Dong W,et al.A systematic review and metaanalysis:safety and efficacy of mesenchymal stem cells therapyfor heart failure[J].Curr Stem Cell Res Ther,2021,16(3):354-365.DOI:10.2174/1574888x15999200820171432.
• [63] Matta A,Ohlmann P,Nader V,et al.A review of the conservative versus invasive management of ischemic heart failure with reduced ejection fraction[J].Curr Probl Cardiol,2024,49(2):102347.DOI:10.1016/j.cpcardiol.2023.102347.
• [64]中华医学会组织修复与再生分会心脏再生学组.自体干细胞移植治疗心力衰竭中国专家共识(2022)[J].中华医学杂志,2023,103(18):1376-1385.DOI:10.3760/cma.j.cn112137-20230217-00224.
• [65]Nashef SA,Roques F,Sharples LD,et al.EuroSCOREⅡ[J].Eur J Cardiothorac Surg,2012,41(4):734-745.DOI:10.1093/ejcts/ezs043.
• [66]Shahian DM,O'Brien SM,Filardo G,et al.The Society of Thoracic Surgeons 2008 cardiac surgery risk models:part1--coronary artery bypass grafting surgery[J].Ann Thorac Surg,2009,88(1 Suppl):S2-S22.DOI:10.1016/j.athoracsur.2009.05.05 3.
• [67] Konstanty-Kalandyk J,Bartus K,Piatek J,et al.Is right coronary artery chronic total vessel occlusion impacting the surgical revascularization results of patients with multivessel disease?A retrospective study[J].Peer J,2018,6:e4909.DOI:10.7717/peerj.4909.
• [68]Khan MR,Kayani WT,Pelton J,et al.Coronary artery bypass grafting versus percutaneous coronary intervention in patients with left ventricular systolic dysfunction[J].Cardiovasc Drugs Ther,2021,35(3):575-585.DOI:10.1007/s10557-020-07063-0.
• [69]Lee G,Malik A,Vervoort D,et al.Revascularization in left ventricular systolic dysfunction:a meta-analysis of kaplan-meier reconstructed individual patient data[J].Can J Cardiol,2024:S0828-282X(24)00414-8.DOI:10.1016/j.cjca.2024.05.023.
• [70]Roth C,Goliasch G,Aschauer S,et al.Impact of treatment strategies on long-term outcome of CTO patients[J].Eur J Intern Med,2020,77:97-104.DOI:10.1016/j.ejim.2020.03.008.
• [71]Nathan A,Hashemzadeh M,Movahed MR.Percutaneous coronary intervention of chronic total occlusion associated with higher inpatient mortality and complications compared with nonCTO lesions[J].Am J Med,2023,136(10):994-999.DOI:10.1016/j.amjmed.2023.06.004.
• [72] Yang L,Guo L,Lv H,et al.Predictors of adverse events among chronic total occlusion patients undergoing successful percutaneous coronary intervention and medical therapy[J].Clin Interv Aging,2021,16:1847-1855.DOI:10.2147/cia.S337069.
• [73]Tian T,Guan C,Gao L,et al.Predictors for adverse outcomes of patients with recanalized chronic total occlusion lesion[J].Eur J Clin Invest,2021,51(2):e13368.DOI:10.1111/eci.13368.
• [74]Farooq V,Serruys PW,Garcia-Garcia HM,et al.The negative impact of incomplete angiographic revascularization on clinical outcomes and its association with total occlusions:the SYNTAX(Synergy Between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery)trial[J].J Am Coll Cardiol,2013,61(3):282-294.DOI:10.1016/j.jacc.2012.10.017.